Clinical Interventions in Aging
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Management of peripheral arterial disease in the elderly: focus on cilostazol
(6041) Total Article Views
Authors: Travis M Falconer, John W Eikelboom, Graeme J Hankey, Paul E Norman
Published Date March 2008 Volume 2008:3(1) Pages 17 - 23
Travis M Falconer1, John W Eikelboom2, Graeme J Hankey3, Paul E Norman1
1School of Surgery, University of Western Australia, Fremantle Hospital, Western Australia; 2Department of Medicine, McMaster University, Hamilton, Canada; 3Department of Neurology, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia
Abstract: Symptomatic and asymptomatic peripheral arterial disease (PAD) is a common problem in the elderly. The management of PAD includes the prevention of cardiovascular events and relief of symptoms – most commonly intermittent claudication (IC). Both require treatment of the causes and consequences of atherothrombosis, but some strategies are more effective for prevention of cardiovascular events and others are more effective for the relief of symptoms. Priorities for the prevention of cardiovascular events include smoking cessation, exercise, antiplatelet therapy, and the treatment of dyslipidemia, hypertension, and diabetes. Walking time and ability are improved by exercise. The benefit of numerous drugs in the treatment of IC has been assessed. The results have generally been disappointing, but there is some evidence that statins and cilostazol (an inhibitor of phosphodiesterase 3) are of benefit. Meta-analyses suggest that cilostazol increases maximum walking distance by 40%–50% and improves other objective measures of walking. The safety profile of cilostazol in patients with PAD appears to be acceptable although the mechanism for its effect on IC is unclear. In addition to risk factor management, treatment with cilostazol should be considered in patients with disabling IC.
Keywords: peripheral arterial disease, intermittent claudication, risk factors, cilostazol
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- New eBook
Have a look at Dr Richard Walker's must read eBook on Amazon Kindle Why we age: Insight into the cause of growing old
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS) is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Have an opinion about one of our articles?
We encourage you to write a letter to the editor.
- Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease
- Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies
- Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
- The cognitive impact of anticholinergics: A clinical review